Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.
暂无分享,去创建一个
Claude Preudhomme | Pierre Fenaux | C. Preudhomme | P. Fenaux | T. Facon | J. Laï | N. Philippe | C. Roche-Lestienne | Thierry Facon | Catherine Roche-Lestienne | Valerie Soenen-Cornu | Nathalie Grardel-Duflos | Jean-Luc Laï | Nathalie Philippe | V. Soenen-Cornu | N. Grardel-Duflos | Nathalie Grardel-Duflos
[1] J. Melo,et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. , 2000, Blood.
[2] C. Sawyers. Chronic myeloid leukemia. , 1999, The New England journal of medicine.
[3] J U Gutterman,et al. The molecular genetics of Philadelphia chromosome-positive leukemias. , 1988, The New England journal of medicine.
[4] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[5] J. Melo,et al. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. , 1996, Blood.
[6] J. Griffin,et al. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. , 2000, Blood.
[7] P. Seeburg,et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.
[8] B. Druker,et al. Roots of Clinical Resistance to STI-571 Cancer Therapy , 2001, Science.
[9] Jürg Zimmermann,et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.
[10] F. Sigaux,et al. Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] O. Witte,et al. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[12] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[13] G. Daley,et al. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. , 1990, Science.
[14] C. Barthe,et al. Roots of clinical resistance to STI-571 cancer therapy. , 2001, Science.
[15] T. Meyer,et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. , 1996, Cancer research.
[16] N. Lydon,et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. , 1997, Blood cells, molecules & diseases.
[17] C. Sawyers,et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.
[18] M. Varella‐Garcia,et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. , 2000, Blood.